Climb Bio (NASDAQ:CLYM) used a presentation at the Leerink Partners Global Healthcare Conference to outline its strategy ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

A phase 1 trial of a human thymus-expressed apoptosis factor in patients with advanced solid tumors: Interim report. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract ...

Antengene Corporation Limited (Antengene), a leading innovative, commercial-stage global biotech company, and UCB, a global ...

B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...

Antibody drugs that go after two targets have already made their mark in blood cancers, but the field is working to improve on the safety and efficacy of this approach. Merck is getting a contender ...

While limited data suggest loncastuximab tesirine plus rituximab may be active in the third line, larger cohorts and longer-term data are needed to definitively determine its effectiveness.

WELLESLEY HILLS, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced it has entered into an exclusive license agreement with Beijing Mabworks Biotech Co., Ltd.

The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD ...

Clinical Trials of ADCs for the Treatment of B-cell Malignancies Five ADCs targeting the B-lineage antigens CD22, CD19 and CD70 are currently in clinical trials for B-cell malignancies: inotuzumab ...

Merck & Co. Inc. is acquiring Curon Biopharmaceutical Ltd.’s bispecific antibody CN-201 that targets CD3 and CD19 for B-cell associated diseases, for up to $1.3 billion. Under the terms of the deal, ...